{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:57:50Z","timestamp":1781701070090,"version":"3.54.5"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373892"],"award-info":[{"award-number":["82373892"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019978","name":"Shanghai Pudong New Area Health Commission","doi-asserted-by":"publisher","award":["PW2023A-11"],"award-info":[{"award-number":["PW2023A-11"]}],"id":[{"id":"10.13039\/501100019978","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019978","name":"Shanghai Pudong New Area Health Commission","doi-asserted-by":"publisher","award":["PWRd2025-01"],"award-info":[{"award-number":["PWRd2025-01"]}],"id":[{"id":"10.13039\/501100019978","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bcp.2026.117682","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:06:21Z","timestamp":1767744381000},"page":"117682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Artemisinin sensitizes triple negative breast cancer to immune checkpoint therapy through suppressing KEAP1-mediated PD-L1 degradation"],"prefix":"10.1016","volume":"245","author":[{"given":"Zehua","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoshuai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiehang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaorui","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5649-0856","authenticated-orcid":false,"given":"Xu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.117682_b0005","doi-asserted-by":"crossref","unstructured":"R.L. Siegel, A.N. Giaquinto, A. Jemal, Cancer statistics, 2024, CA: a cancer journal for clinicians 74(1) (2024) 12-49.","DOI":"10.3322\/caac.21820"},{"issue":"11","key":"10.1016\/j.bcp.2026.117682_b0010","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117682_b0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2026.117682_b0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/imr.12126","article-title":"CAR T cells: driving the road from the laboratory to the clinic","volume":"257","author":"Cheadle","year":"2014","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2026.117682_b0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat. Rev. Can."},{"issue":"2","key":"10.1016\/j.bcp.2026.117682_b0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmed.2013.10.006","article-title":"Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer","volume":"20","author":"Vyas","year":"2014","journal-title":"Trends Mol. Med."},{"issue":"9","key":"10.1016\/j.bcp.2026.117682_b0035","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.bcp.2026.117682_b0040","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117682_b0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117682_b0050","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12916-019-1326-5","article-title":"Recent advances in triple negative breast cancer: the immunotherapy era","volume":"17","author":"Marra","year":"2019","journal-title":"BMC Med."},{"issue":"22","key":"10.1016\/j.bcp.2026.117682_b0055","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bcp.2026.117682_b0060","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1158\/1078-0432.CCR-19-3545","article-title":"FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1","volume":"26","author":"Narayan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117682_b0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu. Rev. Pathol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117682_b0070","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 Study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol."},{"issue":"13","key":"10.1016\/j.bcp.2026.117682_b0075","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S1470-2045(15)00307-1","article-title":"PD-L1 expression as a potential predictive biomarker","volume":"16","author":"Fusi","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117682_b0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.117682_b0085","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117682_b0090","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamaoncol.2016.0639","article-title":"Biomarkers for the clinical use of PD-1\/PD-L1 inhibitors in non-small-cell lung cancer: a review","volume":"2","author":"Sacher","year":"2016","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117682_b0095","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and Function of the PD-L1 Checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.bcp.2026.117682_b0100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/annonc\/mdv615","article-title":"Regulation of PD-L1: a novel role of pro-survival signalling in cancer","volume":"27","author":"Chen","year":"2016","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117682_b0105","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.117682_b0110","doi-asserted-by":"crossref","first-page":"6951","DOI":"10.1038\/s41467-022-34346-x","article-title":"Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation","volume":"13","author":"Shi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117682_b0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semcancer.2021.04.002","article-title":"Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy","volume":"85","author":"Dai","year":"2022","journal-title":"Semin. Can. Biol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117682_b0120","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jnci\/djab121","article-title":"Determining PD-L1 status in patients with triple-negative breast cancer: lessons learned from IMpassion130","volume":"114","author":"Badve","year":"2022","journal-title":"J. Natl Cancer Inst."},{"issue":"8","key":"10.1016\/j.bcp.2026.117682_b0125","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131458","article-title":"PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer","volume":"6","author":"Chen","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.bcp.2026.117682_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106019","article-title":"Future of PD-1\/PD-L1 axis modulation for the treatment of triple-negative breast cancer","volume":"175","author":"Nakhjavani","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117682_b0135","first-page":"382","article-title":"Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity","volume":"4","author":"Wu","year":"2023","journal-title":"Nat Can."},{"key":"10.1016\/j.bcp.2026.117682_b0140","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2016.03.013","article-title":"Three-dimensional culture systems in cancer research: Focus on tumor spheroid model","volume":"163","author":"Nath","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2026.117682_b0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41419-024-06563-3","article-title":"KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bcp.2026.117682_b0150","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol. Cell"},{"issue":"7686","key":"10.1016\/j.bcp.2026.117682_b0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2026.117682_b0160","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/1873-3468.12985","article-title":"E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer","volume":"592","author":"Wang","year":"2018","journal-title":"FEBS Lett."},{"issue":"7670","key":"10.1016\/j.bcp.2026.117682_b0165","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature23669","article-title":"Identification of CMTM6 and CMTM4 as PD-L1 protein regulators","volume":"549","author":"Mezzadra","year":"2017","journal-title":"Nature"},{"issue":"35","key":"10.1016\/j.bcp.2026.117682_b0170","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1038\/s41388-019-0877-4","article-title":"Inhibition of mTOR complex 1\/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced \u03b2-TrCP degradation","volume":"38","author":"Deng","year":"2019","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bcp.2026.117682_b0175","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.ymthe.2020.12.032","article-title":"Emerging role of ubiquitination in the regulation of PD-1\/PD-L1 in cancer immunotherapy","volume":"29","author":"Hu","year":"2021","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.117682_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081885","article-title":"KEAP1 is required for artesunate anticancer activity in non-small-cell lung cancer","volume":"13","author":"Hill","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bcp.2026.117682_b0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/MCB.00868-15","article-title":"Characterizations of three major cysteine sensors of Keap1 in stress response","volume":"36","author":"Saito","year":"2016","journal-title":"Mol. Cell. Biol."},{"issue":"36","key":"10.1016\/j.bcp.2026.117682_b0190","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1038\/s41388-018-0314-0","article-title":"Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy","volume":"37","author":"Zhu","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2026.117682_b0195","first-page":"19","article-title":"Effect of artesunate on liver functions of the wister rat","volume":"1","author":"Onovo","year":"2016","journal-title":"Int. J. Biochem. Bioinformat. Biotechnol. Stud."},{"issue":"10","key":"10.1016\/j.bcp.2026.117682_b0200","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/nm.2471","article-title":"The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine","volume":"17","author":"Tu","year":"2011","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117682_b0205","article-title":"Artemisinin and its synthetic derivatives as a possible therapy for cancer","volume":"6","author":"Konstat-Korzenny","year":"2018","journal-title":"Med. Sci. (Basel Switzerland)"},{"issue":"7","key":"10.1016\/j.bcp.2026.117682_b0210","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/d41573-022-00030-4","article-title":"Challenges and opportunities in the PD1\/PDL1 inhibitor clinical trial landscape","volume":"21","author":"Upadhaya","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bcp.2026.117682_b0215","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s40425-019-0789-4","article-title":"Moving forward to address key unanswered questions on targeting PD-1\/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors","volume":"7","author":"Le","year":"2019","journal-title":"J. Immunother. Can."},{"issue":"3","key":"10.1016\/j.bcp.2026.117682_b0220","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.bcp.2026.117682_b0225","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1158\/0008-5472.CAN-23-2664","article-title":"Post-translational modification of PD-1: potential targets for cancer immunotherapy","volume":"84","author":"Lee","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117682_b0230","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.redox.2012.10.001","article-title":"The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer","volume":"1","author":"Kansanen","year":"2013","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2026.117682_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.751772","article-title":"Immunoregulation by artemisinin and its derivatives: a new role for old antimalarial drugs","volume":"12","author":"Qiu","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117682_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.xinn.2025.101080","article-title":"Single-cell profiling reveals immunoregulation of artemisinin on CD8+ GZMB+ T cells via JAK2-STAT3 in malaria-infected mice","volume":"6","author":"Chen","year":"2025","journal-title":"The Innovation"},{"issue":"5","key":"10.1016\/j.bcp.2026.117682_b0245","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s11427-019-9550-4","article-title":"Dihydroartemisinin regulates the immune system by promotion of CD8(+) T lymphocytes and suppression of B cell responses","volume":"63","author":"Zhang","year":"2020","journal-title":"Sci. China Life Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.117682_b0250","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-019-0264-y","article-title":"The importance of exosomal PDL1 intumour immune evasion","volume":"20","author":"Daassi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2026.117682_b0255","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3389\/fimmu.2017.01597","article-title":"PD-1\/PD-L1 blockade: have we found the key to unleash the antitumor immune response?","volume":"8","author":"Xu-Monette","year":"2017","journal-title":"Front. Immunol."},{"issue":"9402","key":"10.1016\/j.bcp.2026.117682_b0260","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(03)15162-8","article-title":"Artesunate combinations for treatment of malaria: meta-analysis","volume":"363","author":"Adjuik","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bcp.2026.117682_b0265","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/ph3072322","article-title":"Artesunate: the best drug in the treatment of severe and complicated Malaria","volume":"3","author":"Li","year":"2010","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"12","key":"10.1016\/j.bcp.2026.117682_b0270","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.117682_b0275","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1365-2559.2012.04178.x","article-title":"Somatic mutations of the KEAP1 gene in common solid cancers","volume":"60","author":"Yoo","year":"2012","journal-title":"Histopathology"},{"issue":"14","key":"10.1016\/j.bcp.2026.117682_b0280","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1080\/15384101.2018.1496756","article-title":"\u201cKeaping\u201d a lid on lung cancer: the Keap1-Nrf2 pathway","volume":"17","author":"Best","year":"2018","journal-title":"Cell cycle (Georgetown Tex.)"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:13:27Z","timestamp":1781698407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226000134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":56,"alternative-id":["S0006295226000134"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117682","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artemisinin sensitizes triple negative breast cancer to immune checkpoint therapy through suppressing KEAP1-mediated PD-L1 degradation","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117682"}}